Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars EntrestoⓇ - Angiotensin receptor/neprilysin inhibitor NCT03785405 (CLCZ696B2319E1 - extension study) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 2023 Read-out Milestone(s) Publication TBD 92 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation